Prospective Registry Study of Endovascular Treatment for Acute Ischemic Stroke Patients
1 other identifier
observational
2,000
1 country
6
Brief Summary
To investigate the real situation of assessment, diagnosis and treatment of acute ischemic stroke patients with endovascular therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2017
Longer than P75 for all trials
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedFirst Submitted
Initial submission to the registry
August 4, 2023
CompletedFirst Posted
Study publicly available on registry
August 14, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
March 31, 2025
CompletedOctober 8, 2024
January 1, 2024
8 years
August 4, 2023
October 4, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The modified Rankin Scale score at 90 days
The range of the modified Rankin Scale is from 0 to 6. A higher score indicates a worse outcome. 0-No symptoms; 1-No significant disability; 2-Slight disability; 3-Moderate disability; 4-Moderately severe disability; 5-Severe disability; 6-Dead.
90 days
Secondary Outcomes (2)
Successful reperfusion rate
90 days
symptomatic intracranial hemorrhage or death within 90 days after stroke onset.
90 days
Eligibility Criteria
Acute ischemic stroke patients receiving endovascular treatment.
You may qualify if:
- Acute ischemic stroke;
- Brain imaging confirmed intracranial large vessel occlusion: intracranial internal carotid artery (ICA), middle cerebral artery (MCA M1/M2), anterior cerebral artery (ACA A1/A2), basilar artery (BA), vertebral artery (VA V4), and posterior cerebral artery (PCA P1);
- Initiation of any type of endovascular treatment, including mechanical thrombectomy, aspiration, angioplasty, and stenting;
- Informed Consent as documented by signature or fulfilling the criteria for emergency consent/ deferral consent
You may not qualify if:
- Acute intracranial haemorrhage
- No evidence of large vessel occlusion on digital subtraction angiography.
- Patient bedridden or presenting from a nursing home
- Foreseeable difficulties in follow-up due to geographic reasons (e.g. patients living abroad) -
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tingyu-Yilead
- Fujian Medical University Union Hospitalcollaborator
- The First Affiliated Hospital of Nanchang Universitycollaborator
- First People's Hospital of Shenyangcollaborator
Study Sites (6)
Zhangzhou Municipal Hospital
Zhangzhou, Fujian, 36300, China
Gansu provincial hospital of TCM
Lanzhou, Gansu, 730050, China
Jiamusi Central Hospital
Jiamusi, Heilongjiang, 154000, China
Department of Neurology, The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006, China
Songyuan Jilin Oilfield Hospital
Songyuan, Jilin, 138000, China
Shenyang First People's Hospital
Shenyang, Liaoning, 110091, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wen-huo Chen, bachelor
Zhangzhou Affiliated Hospital to Fujian Medical University , Fujian ,China
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 90 Days
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Prospective Registry Study of Endovascular Treatment for Acute Ischemic Stroke Patients in China
Study Record Dates
First Submitted
August 4, 2023
First Posted
August 14, 2023
Study Start
January 1, 2017
Primary Completion
December 31, 2024
Study Completion
March 31, 2025
Last Updated
October 8, 2024
Record last verified: 2024-01